Monophosphoryl Lipid A (mpla) - Toxicology

Relevant Publications

Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth.

Issue Release: 2025

T cell independent antibody responses with class switch and memory using peptides anchored on liposomes.

Issue Release: 2024

Immunoresponsive Gene 1 Facilitates TLR4-agonist-Induced Augmentation of Innate Antimicrobial Immunity.

Issue Release: 2024

Programming Bordetella pertussis lipid A to promote adjuvanticity.

Issue Release: 2024

Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist.

Issue Release: 2024

Tailoring T profiles enhances antibody persistence to a clade C HIV-1 vaccine in rhesus macaques.

Issue Release: 2024

A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.

Issue Release: 2024

Allergen immunotherapy using recombinant allergens improves clinical signs of equine insect bite hypersensitivity.

Issue Release: 2024

TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer.

Issue Release: 2024

Engineering Escherichia coli for constitutive production of monophosphoryl lipid A vaccine adjuvant.

Issue Release: 2024

Monophosphoryl lipid A as a co-adjuvant in methicillin-resistant Staphylococcus aureus vaccine development: improvement of immune responses in a mouse model of infection.

Issue Release: 2024

Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine.

Issue Release: 2024

Respiratory Infection- and Asthma-prone, Low Vaccine Responder Children Demonstrate Distinct Mononuclear Cell DNA Methylation Pathways.

Issue Release: 2024

Pickering emulsion-guided monomeric delivery of monophosphoryl lipid a for enhanced vaccination.

Issue Release: 2024

Targeted Liposomal Co-delivery of an Immunogenic Cell Death Inducer and a Toll-Like Receptor 4 Agonist for Enhanced Cancer Chemo-immunotherapy.

Issue Release: 2024

SHISA3 Reprograms Tumor-Associated Macrophages Toward an Antitumoral Phenotype and Enhances Cancer Immunotherapy.

Issue Release: 2024

Decellularized skin pretreatment by monophosphoryl lipid A and lactobacillus casei supernatant accelerate skin recellularization.

Issue Release: 2024

Immunogenicity and Protective Efficacy of a Multi-Antigen Subunit Vaccine in Mice.

Issue Release: 2024

Enhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticles.

Issue Release: 2024

GSH-responsive polymeric micelles-based augmented photoimmunotherapy synergized with PD-1 blockade for eliciting robust antitumor immunity against colon tumor.

Issue Release: 2024

How to Mitigate Re-identification Risks?

What Are the Types of X-Ray Spectroscopy Used in Toxicology?

How Do B Cells Respond to Toxins?

How Does Nanotechnology Influence Toxicology?

What is Bisphenol A?

What is Histopathology?

What is Herd Immunity?

What is an N95 Respirator?

What are the Challenges in Leachate Collection and Management?

What are the Mechanisms of Lung Damage?

Partnered Content Networks

Relevant Topics